Predict your next investment

HEALTHCARE | Biotechnology

See what CB Insights has to offer


Unattributed | Alive

Total Raised


Last Raised

$5M | 2 yrs ago

About BrickBio

BrickBio is a Boston, Massachusetts-based biotechnology company.

BrickBio Headquarter Location

10 New Street Unit 714

Boston, Massachusetts, 02128,

United States

Latest BrickBio News

BrickBio Validates Its Novel Therapeutic Conjugation Platform at Commercial Scale

Sep 2, 2020

BrickBio has made robust its novel site-specific conjugation process of inserting unnatural amino acids at any site within a protein or antibody News provided by Share this article BOSTON, Sept. 2, 2020 /PRNewswire/ -- BrickBio has demonstrated its ability to insert unnatural amino acids (UAAs), at any site, specifically, within a protein or antibody at commercial scale. These UAAs are used to attach any molecule that may enhance the performance (such as half-life, efficacy, or improved safety) of an antibody or protein therapeutic. BrickBio retains the exclusive rights to use its technology platform for therapeutic development and production, therefore being the sole channel for pharmaceutical partnership and therapeutic development. BrickBio has put in place, and demonstrated, a well-defined conjugation platform process for the development of its lead biologic and for facilitating the work with pharmaceutical partners across partnerships deals. The platform has been validated with extensive data and has been optimized to allow ample throughput for the company's internal efforts, as well as additional capacity to undertake pharmaceutical partnerships and co-development deals. "The BrickBio technology has rapidly evolved and grown over the last year," said James Italia, Vice President of Commercial Development. "The robustness of the platform, speed of innovation, and adaptability of the technology at BrickBio has allowed the company to easily transfer the technology between multiple candidate molecules, including complex antibody scaffolds. The efficiency of the technology enables a homogenous product, thereby allowing increased effectivity of each molecule," Italia concluded. "With the ability to site specifically attach molecules at any site, BrickBio's platform has the potential to revolutionize the field of protein therapeutics and antibody drug conjugates," stated John Boyce, President and CEO of BrickBio as well as Co-Founder of Tiger Gene. "Both the scientific literature and the company have shown that the attachment site matters and can significantly impact the performance of a protein therapeutic," Boyce continued. "The BrickBio platform has the most commercially diverse toolbox of attachment handles (UAAs), taking advantage of the largest number of sites, and as such enabling the greatest flexibility to expedite new therapeutics to patients, repurpose existing therapeutics, and rescue failed biologics," Boyce concluded. SOURCE BrickBio

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing BrickBio

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

BrickBio is included in 1 Expert Collection, including Biopharmaceuticals.



5,880 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.